Key facts
- Editpep’s last known valuation is $34.4M (Dec 2024).
- It has raised $8.6M across 1 recorded rounds; the latest was Early Stage VC ($8.2M) in Dec 2024.
- Notable investors include Berkeley SkyDeck, Berkeley SkyDeck Fund, Lindonlight Collective.
- Editpep has filed 1 Form D with the SEC, most recently Dec 2024 ($8.2M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Editpep
Funding rounds
1 roundsAbout Editpep
Developer of a class of peptides designed to convey CRISPR enzymes into previously untransferable cell types for the treatment of neurological diseases. The company offers a transformative technology that delivers CRISPR molecules as functionalized biologics, without the need for viruses or lipid nanoparticles, enabling the development of gene-editing therapies for brain diseases with greater precision and efficacy.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2021
- Employees
- 5
- Website
- editpep.bio/
- Ownership
- Privately Held (backing)
Editpep doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Editpep shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Editpep in its N-PORT filings yet. We sweep new filings monthly.